Repligen Corp. (RGEN)

HEALTH CARE: PHARMACEUTICALS
SIC: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)

41 SEYON STREET WALTHAM, MA 02453

Repligen Corp. develops novel therapeutics for the treatment of diseases of the central nervous system. The company markets Protein A products which are used in the production of monoclonal antibodies, and SecreFlo, used as an aid in the diagnosis of certain pancreatic disorders.

Data based on most recent fiscal year report
Market Cap5.259 Billion Shares Outstanding52.06 Million Avg Volume630.843 Thousand
1-Yr BETA vs S&P TR1.594 Current Ratio2.12 Quick Ratio1.8
View SEC Filings from RGEN instead.

View recent insider trading info

Funds Holding RGEN (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding RGEN BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

4 Thousand total shares from 2 transactions

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

KURIYEL RALF SENIOR VP, R&D

  • Officer
26,508 2019-12-16 5

SNODGRES JON CHIEF FINANCIAL OFFICER

  • Officer
32,196 2019-12-05 7

BARTHELEMY NICOLAS

  • Director
0 2019-10-24 1

HUNT ANTHONY CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
219,413 2019-09-19 6

DAWES KAREN A

  • Director
117,034 2019-06-17 2

MUIR GLENN P

  • Director
0 2019-06-12 1

COOPER GLENN L MD

  • Director
35,709 2019-05-23 3

RYAN THOMAS F JR

  • Director
4,148 2019-05-15 1

COX JOHN

  • Director
7,236 2019-05-15 1

LIEBER JONATHAN I CHIEF FINANCIAL OFFICER

  • Officer
0 2018-10-01 0

EDDLEMAN ROY T

  • 10% Owner
No longer subject to file 2018-08-09 0

BENJAMIN HOWARD VP BUSINESS DEVELOPMENT

  • Officer
33,908 2017-12-14 0

BVF PARTNERS L P/IL

BIOTECHNOLOGY VALUE FUND L P

BIOTECHNOLOGY VALUE FUND II LP

BVF INVESTMENTS LLC

BVF INC/IL

LAMPERT MARK N

  • SEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSES
No longer subject to file 2017-07-14 0

RUSCHE JAMES R SENIOR VICE PRESIDENT

  • Officer
No longer subject to file 2016-12-31 0

GOLDBERG ALFRED LEWIS

  • Director
40,331 2015-05-21 0

HERLIHY WALTER C PRESIDENT, CEO

  • Officer
  • Director
262,430 2015-05-12 0

GRIFFITH MICHAEL A

  • Director
1,932 2014-11-10 0

WITT DANIEL P SENIOR VICE PRESIDENT

  • Officer
77,999 2014-06-20 0

KELLY WILLIAM J CHIEF ACCOUNTING OFFICER

  • Officer
5,456 2014-02-27 0

HENRY EARL WEBB

  • Director
21,380 2013-05-09 0

HALL MICHAEL CHIEF MEDICAL OFFICER

  • Officer
5,000 2012-03-12 0

SPURR ROBERT CHIEF COMMERCIAL. OFFICER

  • Officer
10,000 2012-03-12 0

RICH ALEXANDER

  • Director
0 2011-12-15 0

Insider Transactions Last 60 Days

Reporting Owners Transaction Date Transaction Code Shares Share Price Acquired or Disposed Shares Owned Following Transaction Combined shares owned after filing Direct/Indirect Ownership 10b-5

KURIYEL RALF - Officer SENIOR VP, R&D

2019-12-16 F 295 $90.43 d 26,508 26,508.00 direct

SNODGRES JON - Officer CHIEF FINANCIAL OFFICER

2019-12-05 M 2,000 $24.50 a 30,239 32,196.00 direct

SNODGRES JON - Officer CHIEF FINANCIAL OFFICER

2019-12-05 M 2,000 d 0 32,196.00 direct

SNODGRES JON - Officer CHIEF FINANCIAL OFFICER

2019-12-05 M 1,957 $26.05 a 32,196 32,196.00 direct

SNODGRES JON - Officer CHIEF FINANCIAL OFFICER

2019-12-05 M 1,957 d 3,170 32,196.00 direct
Click here to report any possible errors with this stock listing.

Elevate your investments